Active substance: mometasone
Form: Nasal spray, suspension
Dosage: Each actuation (spray) delivers approximately 100 mg of suspension containing 50 micrograms of mometasone.
Packaging: Box containing 1 bottle with 18 g of suspension generating at least 140 doses (actuations)
Target: adults (as from 18 years) and children as from 3 years of age
Momex is indicated for the
– Treatment of the symptoms of seasonal allergic or perennial rhinitis in adults and in children 3 years of age and older.
– Treatment of nasal polyps in adults, 18 years of age and older.
Seasonal Allergic or Perennial Rhinitis
Adults:
Children from 3 to 11 years of age.
Momex nasal spray demonstrated a clinically significant onset of action within 12 hours after the first dose in some patients with seasonal allergic rhinitis; however, full benefit of treatment may not be achieved in the first 48 hours. Therefore, the patient should continue regular use to achieve full therapeutic benefit.
Treatment with Momex may need to be initiated some days before the expected start of the pollen season in patients who have a history of moderate to severe symptoms of seasonal allergic rhinitis.
Nasal Polyposis (as from 18 years of age)
The usual recommended starting dose for polyposis is two actuations in each nostril once daily (total daily dose of 200 micrograms).
If after 5 to 6 weeks symptoms are inadequately controlled, the dose may be increased to a daily dose of two sprays in each nostril twice daily (total daily dose of 400 micrograms).
The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.
Prescription drugs. Please contact your doctor.
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.
Dafra Pharma
